TransMedics stock drops 20% after Q1 earnings; valuation still seen as too high despite 40% price fall since October

TransMedics Group, Inc. reported first-quarter earnings that caused its stock to fall over 20%. Despite the stock being nearly 40% cheaper since October, analysts still consider it overvalued due to high expectations baked into its valuation, including sustained revenue growth of 9%-20% and free cash flow margins of 9%-17%. Growth drivers like CHOPS, international expansion, and potential OPO conversion are uncertain or slow-moving, making the current valuation difficult to justify. Investors should be cautious as the company faces challenges meeting these high growth and profitability targets.